Senior Principal Scientist, HTS
AstraZeneca R&D UK, Discovery Sciences, Hit Discovery, England, United Kingdom
Geoff originally joined ICI (predecessor of AstraZeneca) in 1990 as a university industrial placement student, working in molecular enzymology. After graduating in biological and biochemical sciences from the University of Salford, he re-joined the Molecular Enzymology Group as a research scientist in 1992. He worked on numerous projects across all therapy areas carrying out detailed mechanistic characterisation of hits, leads and candidate drugs. He was responsible for establishing key biophysical techniques including Isothermal Titration Calorimetry and Surface Plasmon Resonance into Zeneca in the mid-1990s. Geoff has led teams in both molecular enzymology and biophysics as a Principal Scientist and more recently in HTS having been appointed as Associate Director in 2018. Geoff has subsequently been responsible for leading the HTS department as acting Senior Director since early 2020. Geoff has been able to contribute to the identification and characterisation of several marketed drugs including Iressa, Crestor, Caprelsa, Koselugo and Tagrisso. He has a strong publication track record, contributing to over 40 original research articles, reviews and book chapters, with an h-index of 28. He is currently on the editorial boards for the journals ADMET & DMPK and SLAS Discovery. Geoff is a frequently invited reviewer for a number of journals including Scientific Reports, J. Med. Chem., Drug Discovery Today, Biochemical Pharmacology and European Biophysics Journal. In 2017 he was awarded the SLAS Reviewer Excellence Award. Geoff has also been involved in organising and presenting at external meetings including the ELRIG Discovery Technologies meetings and the Next Generation Biophysics Meeting organised jointly with Imperial College London and the Laboratory of Molecular Biology.
Disclosure information not submitted.
Sunday, February 6, 2022
8:30 AM – 4:30 PM